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The use of antibiotics for treating exacerbations in patients with chronic obstructive 
pulmonary disease (COPD) has been a topic of controversy since first studied in the 1950s and 
1960s. This paper analyzes the effects of a course of antibiotics on time until next exacerbation in 
patients with COPD. Five recent randomized control trials were examined. The antibiotic most 
often studied was azithromycin, a macrolide. Azithromycin decreased the length of time to first 
exacerbation compared to placebo in three studies; two other studies depicted sub analyses to 
support azithromycin as superior to placebo. Overall, antibiotics decreased the length of time 
between exacerbations, especially azithromycin. Treating exacerbations with antibiotics was more 
effective in certain patient populations such as patients of older age, a smoking history, or a milder 
form of COPD. It is important for these patients to be screened appropriately with continuous 
follow-up when administering azithromycin to decrease exacerbations in patients with COPD. 
 
BACKGROUND 
The World Health Organization projects chronic obstructive pulmonary disease (COPD) 
to be the 3rd leading cause of death by 2030.1 COPD is characterized by persistent respiratory 
symptoms and airflow limitation due to airway and/or alveolar abnormalities usually caused by 
significant exposure to noxious particles or gases.2 It has deleterious health effects that accumulate 
over the lifespan, typically manifest in older age and are common among smokers.  
 
Prevalence 
The prevalence of COPD in the United States varies from <4% in Hawaii, Colorado, and 
Utah to >9% in Alabama, Tennessee, Kentucky, and West Virginia. States with the highest COPD 
prevalence are clustered along the Ohio and lower Mississippi Rivers.3 Worldwide prevalence and 
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mortality rates of COPD are grimmer and are expected to place great strain on worldwide health 
care systems in the coming decades. 
Pathophysiology 
COPD is a culmination of the effects of the inflammatory response system which damages 
the airways resulting in airway limitation, obstruction and/or loss of elastic recoil. Triggers activate 
neutrophils and macrophages in the inflammatory response system, which release proteases that 
cause tissue destruction and promote hypersecretion of the airways. When the destruction happens 
at the level of the alveoli, there is a loss of elastic recoil and surface area resulting in a decrease of 
oxygen exchange. All these factors can result in pulmonary hypertension, respiratory infections, 
and other comorbidities.4  
Diagnosis of the disease is obtained by assessing patient symptoms, evaluating risk factors 
and pulmonary function testing. The classic signs of a patient with COPD are frequent respiratory 
exacerbations, a barrel shaped chest, and hyperinflation of the lungs.4 The Anthonisen Criteria 
defines an exacerbation as an increase of symptoms that a patient with COPD experiences because 
of their condition. Symptoms include an increase in sputum production, sputum volume, dyspnea 
and cough. 5 Exacerbations can lead to increased susceptibility to infections, an increase in 
hospitalizations and a decrease in quality of life.  
Standards of Care and Treatment 
The current standard treatment regimen for COPD in the 2018 Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) report involves a long or short acting 
antimuscarinic/anticholinergic inhaler and in some cases concurrent corticosteroids. Antibiotics 
are part of a later course of treatment that includes azithromycin given 250mg per day or 500mg 
given three times per week or erythromycin given 500mg twice per day for one year in patients 
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prone to exacerbations. This regimen of antibiotics, compared to usual care, has been shown to 
reduce the risk of exacerbations compared to usual care. However, no data are available showing 
the efficacy or safety of chronic azithromycin treatment to prevent COPD exacerbations beyond 
one year of treatment.6 The use of azithromycin as part of the COPD treatment regimen is 
continuously being reviewed because of concerns about antibiotic resistance, adverse effects of 
impaired hearing, and development of cardiac abnormalities such as prolonged QT interval.7 
 
Antibiotic Stewardship 
 Finding the balance between the benefits of antibiotic therapy to individual patients and 
the potential harms to both patients and society created by antibiotic overuse resulting in microbial 
resistance is especially relevant to COPD patients. These patients are at higher risk for infections 
and exacerbations, which have major negative health outcomes. COPD exacerbations are 
considered multifactorial; evidence suggests that bacterial infections are their primary cause.8,9 As 
such, COPD exacerbations are frequently controlled with antibiotics. To decrease the risk of drug 
resistant bacteria antibiotics should be used wisely. The inappropriate use of antibiotics, both 
overuse and misuse, is considered a major public health concern. Antibiotic stewardship is a 
coordinated program that involves a collaborative effort to educate prescribers about the correct 
ways to administer antibiotics to reduce the risk of drug resistance bacteria and the spread of those 
resistant strains.10 
Other research 
Other diagnostic and treatment modalities to reduce exacerbations may be better than 
initiating antibiotic therapy empirically. Although bacterial infections are the most likely cause of 
exacerbations, confirmation of this hypothesis by measurements of the bacterial loads in the 
airways is limited. Analysis of sputum and swab cultures are unremarkable. Measuring 
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procalcitonin levels to assess for pulmonary infection as the cause of exacerbations was explored.11 
This investigation found these levels to be accurate for diagnosing infection; however, the quality 
of the available evidence was low to moderate. Another study examined non-invasive ventilation 
in ICU patients, instead of oral antibiotics, for decreasing the duration and frequency of 
exacerbations.12 Although non-invasive ventilation was found to be superior to antibiotics, the 
findings were limited to hospitalized patients. 
Existing Research 
A systemic review by the Cochrane Library published in 2013 analyzed whether regular 
treatment of COPD patients with antibiotics reduced exacerbations. Seven randomized controlled 
trials investigated azithromycin, erythromycin, clarithromycin, and moxifloxacin. On average, the 
participants were 66 years old and had either moderate or severe COPD. The results showed that 
the use of continuous antibiotics, especially with a macrolide, resulted in a clinically significant 
benefit for reducing exacerbations and lengthening the time to first exacerbation in patients with 
COPD.13  
This paper examines the effect of antibiotic therapy compared to no antibiotic therapy on 
length to first exacerbation in patients diagnosed with COPD (stages 1-4). The 2018 GOLD 
guidelines mention treatment with macrolide antibiotics but warn of adverse effects, such as of 
impaired hearing and cardiovascular abnormalities, in particular, QT interval prolongation. In view 
of potential serious adverse effects, determining whether antibiotics should be continued as part of 
standard treatment is relevant to practice. This paper builds upon the 2013 Cochrane review which 
found that the continuous use of antibiotics up to one year, especially azithromycin, resulted in a 
clinically significant benefit of reducing COPD exacerbations. Since Cochrane’s review was 
conducted in 2013, more recent investigations are explored in this paper. While the long-term use 
of antibiotics remains controversial because there are no studies which measure their use past one 
5 
 
year,14 the role of antibiotics for reducing COPD exacerbations may still be beneficial for 
decreasing patient morbidity and burdens on the health care system.  
DISCUSSION 
Literature search 
The literature search accessed several databases including PubMed, Science Direct, 
Cochrane Library, Trip, and International Journal of COPD. The search terms used were chronic 
obstructive pulmonary disease/COPD AND antibiotics/azithromycin/macrolide/doxycycline 
AND exacerbations/relapse/recurrence. Articles were screened by title and abstract. Articles were 
excluded if they did not address the topic question with specific analysis on time to first/next 
exacerbation and frequency of exacerbations. For those studies that were not excluded, a full text 
of the article was obtained, and further exclusion was made based on content. The reference lists 
were screened and cross referenced for relevant articles and systemic reviews to ensure 
thoroughness of the review. A step-by-step critique of each article was performed to check for 
quality and validity. Most of the articles that were chosen were published within the last 5 years 
and contained most of their cited references within the last 5 years.  
Summary of Evidence 
Five randomized controlled trials were included in this review. Four studies were published 
between 2013 and 2018 with one article published in 2011. Three studies measured time to first 
exacerbation with azithromycin compared to placebo,15-17  while another study compared 
doxycycline to placebo.18 The fifth study reviewed a regimen of three different antibiotics 
(moxifloxacin, doxycycline, and azithromycin) to obtain results in a sub analysis on time to first 
exacerbation and frequency of exacerbations.19 Azithromycin is a macrolide, doxycycline is a 
tetracycline, and moxifloxacin is a fourth-generation fluoroquinolone. The study durations varied 
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from three months to two years and all used intention-to-treat analysis. The focus for this review 
was time to next exacerbation (TTNE). 
Four out of the five studies quantified TTNE. The study by Albert et al determined that the 
median TTNE with azithromycin was 266 days compared to 174 days with placebo.15 Han et al 
showed a median time of 377 days with azithromycin plus steroid and 110 days with steroid only.16 
Uzun et al determined a median time of 130 days with azithromycin and 59 days with placebo.17 
All three studies showed a reduction in TTNE for a length of one year with azithromycin compared 
to without it. These findings are consistent with those found in the 2013 Cochrane review.  
A study by Velzen et al compared a 7-day course of doxycycline to placebo and found no 
statistical difference in TTNE.18 The median TTNE for the doxycycline and placebo groups were 
148 days and 161 days respectively.  
A study performed by Brill et al did not specifically quantify TTNE but rather in a sub 
analysis quantified the frequency of exacerbations between different antibiotics (moxifloxacin, 
doxycycline, and azithromycin) and placebo when taken for a period of 13 weeks. According to 
this study, the exacerbations in the doxycycline group increased compared to placebo, whereas in 
the azithromycin group they were statistically comparable to placebo. Azithromycin showed the 
least frequency of exacerbations at 0.83 and doxycycline had the highest frequency of 2.05. 19 
These findings are consistent with the results for azithromycin found in studies by Albert et al and 
Uzun et al. Albert et al found that azithromycin reduced exacerbations to a frequency of 1.48 
compared to placebo’s frequency of 1.83, a rate ratio of 0.83.15 Uzun et al also showed a frequency 
reduction of exacerbations, 1.32 for azithromycin and 3.22 for placebo; a rate ratio of 0.6.16 No 
statistically significant decrease of exacerbations was found with doxycycline by Velzen et al.15-18 
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These results continue to confirm azithromycin as the better antibiotic for decreasing exacerbations 
in COPD patients.  
The studies’ findings are summarized in Table 1. A summary of rate ratios and P values is 













Time to first 
exacerbation 1,142 
Azithromycin 
250mg/day x1 year 
or placebo 
266 days 174 days P<0.001 
Han 
2014 
Time to first 
exacerbation 1,113 
Azithromycin 
250m/day x1 year or 
placebo 
377 days 110 days P=0.0002 
Uzun 
2014 





500mg 3x per week 
x1 year or placebo 
130 days 59 days P=0.001 
Velzen 
2017 
Time to next 
exacerbation 305 
Doxycycline 100mg 
(200mg on day 1) 
x7days or placebo 









400m/day for 5 days 





250mg 3x per week 
















Table 1. Characteristics of Studies Reviewed. 
 
Study Rate ratio P value 
Brill 2015 Moxifloxacin 1.36, Doxycycline 2.05, 
Azithromycin 0.83 
Moxifloxacin P=0.44, Doxycycline P=0.06, 
Azithromycin P=0.66 
Uzun 2014 Azithromycin 0.6 P=0.003 
Albert 2011 Azithromycin 0.83 P=0.008 
Table 2. Frequency of exacerbations. 
 
Study interventions and patient parameters 
All five studies had patients with a median age ranging from 64 to 70 years old, a history 
of smoking, and a clinical diagnosis of COPD.17-19 Albert et al and Han et al included patients on 
continuous oxygen.15,16 Three studies used an antibiotic for a total of one year. The other two 
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studies used shorter courses of seven days or 13 weeks. All study parameters were analyzed using 
a hazard ratio analysis. Han et al specifically looked at patient characteristics that predicted benefit 
from antibiotic therapy of exacerbations. The parameters which favored the benefits of 
azithromycin were age >65, former smoking status, and diagnosis of mild COPD at GOLD stage 
2.16 Albert et al found that the same patient parameters were associated with benefits from 
azithromycin therapy.15 Velzen et al described a different outcome of patient parameters favoring 
doxycycline with age <65, no difference with smoking status, and slight favor for moderate form 
of COPD GOLD stage 3.18 This evidence suggests that azithromycin reduces exacerbations, 
especially in patients that are >65 years old, are former smokers, and have a milder GOLD stage 
of COPD. See Appendix for figures on patient parameters and hazard ratios.  
These studies were limited because they lacked a comparison with a placebo, whereas Brill 
et al did find statistically significant benefits of antibiotics compared to placebo. Furthermore, 
none of the studies examined the use of antibiotics for over a year. Nonetheless, the studies did 
have results that were statistically significant for the comparisons that were made.13 
 
CONCLUSION 
 The evidence about antibiotic use for COPD exacerbations that was presented in the 2013 
Cochrane Review is updated by this paper. Current evidence suggests that azithromycin is 
effective for decreasing TTNE and that patients experiencing an increase in exacerbations may 
benefit from adding azithromycin to the usual treatment regimen. Furthermore, specific subgroups 
of patients are likely to benefit more than others, including patients older than age 65, former 
smokers, and patients with a milder form of COPD. Factors that must be considered before 
administering antibiotics for COPD exacerbations are patient age, smoking status and history, 
severity of COPD, other comorbidities, and the risk versus benefits of using antibiotics in general. 
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Continuous and regular follow-up for monitoring these patients is recommended while they are on 
antibiotics for COPD exacerbations.  
Evidence supporting the benefits of azithromycin over its adverse effects of impaired 
hearing and cardiac abnormalities is limited. Researchers suggest including a baseline ECG and 
hearing test as part of medication pre-administration.20 When azithromycin is not a treatment 
option for patients, other antibiotics that may be used include dirithromycin, ofloxacin, 
ciprofloxacin and trimethoprim-sulfamethoxazole.21  
Future research 
Additional studies are recommended to address gaps in knowledge such as studies 
comparing antibiotic regimens for greater than one year, comparing different regimens of 
azithromycin, directly comparing other classes of antibiotics to azithromycin, examining the 
effects of different antibiotic classes on the specific subset of patients mentioned, and specifically 
screening for side effects such as cardiac abnormalities and hearing deficits.   
Current studies are underway to determine whether the benefits of treatment of COPD 
exacerbations with antibiotics outweigh the risks of antimicrobial resistance and side effects. The 
results of the ABACOPD study by BioMed Central Pulmonary Medicine are expected soon. This 
sufficiently powered double-blind placebo-controlled trial evaluates whether antibiotics, known to 
increase antibiotic resistance, are really needed in a well-defined patient cohort receiving state of 
the art treatment in all other aspects including systemic corticosteroids.22 Another study called The 
Belgian Trial by the International Journal of COPD should be released soon. It is a randomized, 
double-blinded, placebo-controlled trial that investigates whether azithromycin might be effective 
and safe when initiated at the onset of a severe exacerbation for a limited duration and at a low 
dose. Its purpose is to establish a more appropriately restricted use of azithromycin so that the 






Figure 1. Han 2014 hazard ratio for exacerbations patient subgroup analyses.16  
Excerpted from Han MK, Tayob N, Murray S, Dransfield MT, Washko G, Scanlon PD, et al. 
Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily 
azithromycin therapy. American Journal of Respiratory and Critical Care Medicine. 





Figure 2 & 3. Albert 2011 hazard ratio for exacerbations patient subgroup analyses.15 
Excerpted from Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JD, Criner GJ, et al. 





Figure 4. Velzen 2017 hazard ratio for exacerbations patient subgroup analyses.18 
Excerpted from van Velzen P, ter Riet G, Bresser P, Baars JJ, van den Berg BT, van den Berg 
JW, et al. Doxycycline for outpatient-treated acute exacerbations of COPD: A randomised 
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